Mucosal immunization of mice using CpG DNA and/or mutants of the heat-labile enterotoxin of Escherichia coli as adjuvants

Vaccine

Volumn 19, Issue 27, 2001, Pages 3759-3768

  McCluskie, Michael J ^a   Weeratna, Risini D ^a   Clements, John D ^b   Davis, Heather L ^a,c,d  

^a Coley Pharmaceutical Canada ^*  (Canada)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Adjuvant; CpG; Mucosal

Indexed keywords

CYCLIC AMP; ESCHERICHIA COLI ENTEROTOXIN; HEPATITIS B SURFACE ANTIGEN; IMMUNOLOGICAL ADJUVANT; OLIGODEOXYNUCLEOTIDE; TETANUS TOXOID;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BACTERIUM MUTANT; BETA CHAIN; CONTROLLED STUDY; CPG ISLAND; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; ESCHERICHIA COLI; FEMALE; HEPATITIS B; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOSTIMULATION; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; TETANUS; TH1 CELL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BACTERIAL TOXINS; CPG ISLANDS; ENTEROTOXINS; ESCHERICHIA COLI PROTEINS; FEMALE; IMMUNITY, MUCOSAL; IMMUNIZATION SCHEDULE; MICE; MICE, INBRED BALB C; MUTATION; OLIGODEOXYRIBONUCLEOTIDES;

EID: 0035859288     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(01)00088-3     Document Type: Article

References (53)

1. A nontoxic mutant of cholera toxin elicits Th2-type responses for enhanced mucosal immunity
2. Mutants in the ADP-ribosyltransferase cleft of cholera toxin lack diarrheagenicity but retain adjuvanticity
3. LT(R192G), a non-toxic mutant of the heat-labile enterotoxin of Escherichia coli, elicits enhanced humoral and cellular immune responses associated with protection against lethal oral challenge with Salmonella spp.
4. Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis
5. Bacterial toxins as mucosal adjuvants
6. The role of cAMP in mucosal adjuvanticity of Escherichia coli heat-labile enterotoxin
7. Effects of site-directed mutagenesis of Escherichia coli heat-labile enterotoxin on ADP-ribosyltransferase activity and interaction with ADP-ribosylation factors
8. Comparison of intranasal and intramuscular immunization against human immunodeficiency virus type 1 with a DNA-monophosphoryl lipid A adjuvant vaccine
9. HIV-1 neutralizing antibodies in the genital and respiratory tracts of mice intranasally immunized with oligomeric gp160
10. Oral adjuvants enhance IgA responses to Streptococcus mutans
11. Effective immunity to dental caries: Enhancement of salivary anti-Streptococcus mutans antibody responses with oral adjuvants
12. Mucosal and systemic immune responses in BALB/c mice to Bacteroides gingivalis fimbriae administered orally
13. Effect of MDP-Lys(L18) as a mucosal immunoadjuvant on protection of mucosal infections by Sendai virus and rotavirus
14. Systemic and mucosal immune responses of mice to aluminium-adsorbed or aluminium-non-adsorbed tetanus toxoid administered intranasally with recombinant cholera toxin B subunit
15. Intranasal or subcutaneous co-administration of recombinant cholera toxin B subunit stimulates only a slight or no level of the specific IgE response in mice to tetanus toxoid
16. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes
17. Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21
18. CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice
19. CpG DNA as mucosal adjuvant
20. Immunostimulatory DNA is a potent mucosal adjuvant
21. CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus
22. Structure and function of cholera toxin and the related Escherichia coli heat-labile enterotoxin
23. The mucosal adjuvant activities of ADP-ribosylating bacterial enterotoxins
24. The adjuvant effect of Vibrio cholerae and Escherichia coli heat-labile enterotoxins is linked to their ADP-ribosyltransferase activity
25. Cholera toxin and cholera B subunit as oral-mucosal adjuvant and antigen vector systems
26. Musosal immunoadjuvant activity of recombinant Escherichia coli heat-labile enterotoxin and its B subunit: Induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with influenza virus surface antigen
27. Recombinant cholera toxin B subunit acts as an adjuvant for the mucosal and systemic responses of mice to mucosally co-administered bovine serum albumin
28. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine
29. Escherichia coli heat-labile enterotoxin B subunits supplemented with a trace amount of the holotoxin as an adjuvant for nasal influenza vaccine
30. CpG motifs in bacterial DNA trigger direct B-cell activation
31. CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma
32. CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL
33. Bacterial DNA induces murine interferon-gamma production by stimulation of interleukin-12 and tumor necrosis factor-alpha
34. Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12
35. Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides
36. Unique palindromic sequences in synthetic oligonucleotides are required to induce INF and augment INF-mediated natural killer activity
37. Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA
38. Intranasal immunization of mice with CpG DNA induces strong systemic and mucosal responses that are influenced by other mucosal adjuvants and antigen distribution
39. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant Hepatitis B surface antigen
40. Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin
41. Mutational analysis of the role of ADP-ribosylation activity and GM1-binding activity in the adjuvant properties of the Escherichia coli heat-labile enterotoxin towards intranasally administered keyhole limpet hemocyanin
42. CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice
43. CpG DNA is a novel non-toxic adjuvant which induces stronger immune responses than many conventional adjuvants
44. Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes
45. TH2-type cytokines in asthma
46. The pathology of asthma
47. Mucosally induced immunoglobulin E-associated inflammation in the respiratory tract
48. Long term prevention of allergic lung inflammation in a mouse model of asthma by CpG oligodeoxynucleotides
49. Oligodeoxynucleotides containing CpG motifs modulate the allergic TH2 response of BALB/c mice to Bet v 1, the major birch pollen allergen
50. Immunostimulatory DNA sequences inhibit IL-5, eosinophilic inflammation, and airway hyperresponsiveness in mice
51. Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma
52. Regulation of T-helper type 2 cell and airway eosinophilia by transmucosal coadministration of antigen and oligodeoxynucleotides containing CpG motifs
53. CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma